selected publications
-
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.
Cancer discovery.
2022
Academic Article
GET IT
Times cited: 7 - DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient. 2022 GET IT
-
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.
ESMO open.
2022
Academic Article
GET IT
Times cited: 2 -
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.
Science (New York, N.Y.).
2022
Academic Article
GET IT
Times cited: 22 -
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022
Academic Article
GET IT
Times cited: 8 -
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022
Academic Article
GET IT
Times cited: 3 -
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
Journal for immunotherapy of cancer.
2022
Academic Article
GET IT
Times cited: 11 -
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer.
Nature communications.
2022
Academic Article
GET IT
Times cited: 29 -
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022
Academic Article
GET IT
Times cited: 4 -
FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.
2022
GET IT
Times cited: 1 -
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell.
2022
Academic Article
GET IT
Times cited: 86 -
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2022
Academic Article
GET IT
Times cited: 8 -
Low-grade endometrial stromal sarcoma-like tumors in male with JAZF1 gene fusions.
2021
GET IT
Times cited: 1 -
Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls.
Genes, chromosomes & cancer.
2021
Academic Article
GET IT
Times cited: 9 -
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
The oncologist.
2021
Academic Article
GET IT
Times cited: 15 -
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
European journal of cancer (Oxford, England : 1990).
2021
Academic Article
GET IT
Times cited: 13 -
Melanoma models for the next generation of therapies.
Cancer cell.
2021
Review
GET IT
Times cited: 48 -
The management of metastatic GIST: current standard and investigational therapeutics.
Journal of hematology & oncology.
2021
Review
GET IT
Times cited: 63 -
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies.
Cancer discovery.
2020
Academic Article
GET IT
Times cited: 36 -
Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling.
The Journal of biological chemistry.
2020
Academic Article
GET IT
Times cited: 14 -
Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020
Comment
GET IT
Times cited: 21 -
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes.
JCO precision oncology.
2020
Academic Article
GET IT
Times cited: 1209 -
ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.
The Journal of clinical investigation.
2020
Academic Article
GET IT
Times cited: 22 -
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
Cell reports.
2020
Article
GET IT
Times cited: 1 -
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2020
Academic Article
GET IT
Times cited: 52 -
HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020
Academic Article
GET IT
Times cited: 4 -
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet. Oncology.
2020
Academic Article
GET IT
Times cited: 177 -
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
JAMA oncology.
2020
Academic Article
GET IT
Times cited: 92 -
MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants.
2019
GET IT
Times cited: 8 -
Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions.
The American journal of surgical pathology.
2019
Academic Article
GET IT
Times cited: 68 -
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
The oncologist.
2019
Academic Article
GET IT
Times cited: 20 -
Identification of Cancer Drivers at CTCF Insulators in 1,962 Whole Genomes.
Cell systems.
2019
Academic Article
GET IT
Times cited: 39 -
Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2018
Academic Article
GET IT
Times cited: 52 -
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.
Investigational new drugs.
2018
Academic Article
GET IT
Times cited: 26 -
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.
Journal of hematology & oncology.
2018
Review
GET IT
Times cited: 35 -
COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.
The Journal of clinical investigation.
2018
Academic Article
GET IT
Times cited: 24 -
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
Cell reports.
2018
Academic Article
GET IT
Times cited: 45 -
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 39 -
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.
Cancer cell.
2017
Academic Article
GET IT
Times cited: 45 -
A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors.
Head and neck pathology.
2017
Academic Article
GET IT
Times cited: 15 -
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.
Ophthalmology.
2017
Academic Article
GET IT
Times cited: 80 -
ETV1-Positive Cells Give Rise to BRAFV600E -Mutant Gastrointestinal Stromal Tumors.
Cancer research.
2017
Academic Article
GET IT
Times cited: 12 -
OncoKB: A Precision Oncology Knowledge Base.
JCO precision oncology.
2017
Academic Article
GET IT
Times cited: 394 -
Patient perspectives on ipilimumab across the melanoma treatment trajectory.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
2017
Academic Article
GET IT
Times cited: 12 -
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 92 -
Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Oral oncology.
2016
Letter
GET IT
Times cited: 6 -
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon.
PloS one.
2016
Academic Article
GET IT
Times cited: 18 -
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
JAMA oncology.
2016
Academic Article
GET IT
Times cited: 201 -
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma.
Sarcoma.
2016
Academic Article
GET IT
Times cited: 693 -
Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape.
Science (New York, N.Y.).
2016
Academic Article
GET IT
Times cited: 250 -
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.
Nature genetics.
2016
Academic Article
GET IT
Times cited: 189 -
Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.
The American journal of surgical pathology.
2016
Academic Article
GET IT
Times cited: 187 -
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
The oncologist.
2015
Academic Article
GET IT
Times cited: 23 -
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.
Nature.
2015
Academic Article
GET IT
Times cited: 162 -
Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
Cancer discovery.
2015
Academic Article
GET IT
Times cited: 95 -
Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature.
Annals of surgical oncology.
2015
Review
GET IT
Times cited: 40 -
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
Nature genetics.
2014
Academic Article
GET IT
Times cited: 386 -
Organoid cultures derived from patients with advanced prostate cancer.
Cell.
2014
Academic Article
GET IT
Times cited: 983 -
High-risk features in radiation-associated breast angiosarcomas.
British journal of cancer.
2013
Academic Article
GET IT
Times cited: 48 -
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
Nature medicine.
2013
Academic Article
GET IT
Times cited: 220 -
Visualization of the interstitial cells of cajal (ICC) network in mice.
Journal of visualized experiments : JoVE.
2011
Academic Article
GET IT
Times cited: 12 -
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Nature.
2010
Academic Article
GET IT
Times cited: 243 -
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers.
Nature reviews. Cancer.
2010
Review
GET IT
Times cited: 876 -
Chromatin remodeling and cancer, Part I: Covalent histone modifications.
Trends in molecular medicine.
2007
Review
GET IT
Times cited: 334 -
Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling.
Trends in molecular medicine.
2007
Review
GET IT
Times cited: 185 -
Synaptic vesicle mobilization is regulated by distinct synapsin I phosphorylation pathways at different frequencies.
Neuron.
2003
Academic Article
GET IT
Times cited: 270 -
Regulation of neurotransmitter release by synapsin III.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
2002
Academic Article
GET IT
Times cited: 126 -
Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons.
The Journal of physiology.
2002
Academic Article
GET IT
Times cited: 94 -
Synapsin dispersion and reclustering during synaptic activity.
Nature neuroscience.
2001
Academic Article
GET IT
Times cited: 293